RxDoctor Payments Data

Joseph Lamar, MD

Internal Medicine · Hickory, NCNPI 1073928883

Payments from drug & device makers

$4,345in general payments, 2019–2025

Across 94 payments — averaging $46.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$1K
  • Intuitive Surgical$567
  • Regeneron Healthcare Solutions, Inc.$324
  • AstraZeneca$276
  • Medical Device Business Services, Inc.$251
  • Olympus America Inc.$230
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$1,42633%
  • Food & beverage$2,91967%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,345 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$87,607
Medicare patients
217
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$50,336
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$44,770
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$21,727
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$21,182
Spiriva RespimatTiotropium Bromide15$7,826
SymbicortBudesonide/Formoterol Fumarate28$6,393
Albuterol Sulfate HfaAlbuterol Sulfate76$1,631
Omeprazole23$388
Fluticasone Propionate14$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$180$71,518121 claims
AstraZenecaBreztri Aerosphere, Symbicort$276$51,16391 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$76$29,55350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →